MedTrace Logo

Mortality and Symptom Burden Post Hospitalisation With COPD

NCT03657121 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 447

Last updated 2021-03-03

No results posted yet for this study

Summary

Chronic Obstructive Pulmonary Disease (COPD) is a common progressive lung disease which causes breathlessness and frequent exacerbations, with patients often requiring hospitalisation. Patients with severe COPD commonly become housebound and lose their independence. They have a higher symptom burden than those with incurable lung cancer, yet are less likely to receive specialist palliative care, or to have been engaged in advance care planning (where patients discuss and often document their wishes regarding their future care). Hospital admissions become increasingly common towards the end-of-life; therefore, hospitalisation is a good opportunity to identify patients at risk of poor outcome. Such patients may wish to consider alternatives to admission and avoid intrusive treatments. Unfortunately, predicting which patients are likely to die in the near future is challenging thus far.

The first step required to improve provision of palliative care services, and ensure patients are given the opportunity to make truly informed decisions about their future care, is accurate identification of those most likely to benefit.

Well-designed clinical (prognostic) tools outperform clinician judgement in most settings. The investigators will compare the accuracy of one year mortality prediction of several clinical tools in patients who survive a COPD exacerbation requiring admission. This will initially be performed using existing data collected during previous research (the 1,593 patient validation study for the PEARL score - Previous admissions, extended Medical Research Council Dyspnoea score, Age, Right and Left heart failure), then confirmed in at least 310 patients admitted uniquely and consecutively with an exacerbation of COPD. The latter group of patients will be invited to participate in a longitudinal follow-up study, assessing symptom burden, quality of life, and readmissions over one year.

Conditions

  • Pulmonary Disease, Chronic Obstructive
  • Pulmonary Disease, Obstructive
  • Emphysema
  • Chronic Bronchitis
  • Chronic Bronchitis With Airways Obstruction
  • Chronic Bronchitis With Acute Exacerbation

Sponsors & Collaborators

  • National Institute for Health Research, United Kingdom

    collaborator OTHER_GOV

  • Newcastle-upon-Tyne Hospitals NHS Trust

    collaborator OTHER

  • Hospice UK

    collaborator UNKNOWN

  • Northumbria Healthcare NHS Foundation Trust

    lead OTHER

Principal Investigators

  • Sarah M Gillespie, MBChB · Northumbria Healthcare NHS Foundation Trust

Eligibility

Min Age
35 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-16
Primary Completion
2020-12-18
Completion
2020-12-18

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03657121 on ClinicalTrials.gov